Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Synaptamine
Austin, Texas, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Synaptamine markets dietary supplements designed to address Reward Deficiency Syndrome through dopamine homeostasis support. The company's flagship product, KB220Z, uses precursor amino acids and herbal ingredients to support neurotransmitter synthesis. The company also markets the Genetic Addiction Risk Score (GARS) test to assess genetic predisposition toward RDS[1][7].
- Therapeutic areas
- PsychiatryMetabolic Disorders
- Modalities
- Dietary supplementsGenetic testing
- Industry
- Molecular Diagnostics
02
Partnerships
LaVita RDS (Synaptamine licensee, Lehi, Utah)Sanus Biotech (Austin, Texas)NuPathways Inc. (SynaptaGenX licensee)Weider Nutrition (PhenCal licensee)Nature's Plus (SynaptaLean licensee)IGENE LLCLifeGen, Inc.Geneus HealthDominion Diagnostics
Beyond the preview
Go deeper on Synaptamine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synaptamine.